These findings not only provide novel mechanistic insights into DCM pathogenesis but also highlight the DDR-IFI16 interface as a potential target for future therapeutic development aimed at halting or reversing adverse cardiac remodeling in patients with dilated cardiomyopathy. The gene discussed is IFI16; the disease is dilated cardiomyopathy.